It was initially called T cell growth factor, but the name was changed in 1978 to IL-2 (interleukin-2) by the Interlaken cytokine nomenclature committee.
Interleukin 3 | Interleukin 6 | Interleukin 5 | Interleukin 18 | Interleukin 17 | Interleukin 4 | Interleukin 15 | Interleukin 8 | Interleukin 32 | Interleukin 24 | Interleukin 2 | Interleukin 12 | interleukin 6 (IL-6) | Interleukin-3 receptor | Interleukin 22 | Interleukin 13 | Interleukin 12 receptor, beta 2 subunit | Interleukin 10 |
PCT has the greatest sensitivity (85%) and specificity (91%) for differentiating patients with systemic inflammatory response syndrome (SIRS) from those with sepsis, when compared with IL-2, IL-6, IL-8, CRP and TNF-alpha.
The expression of this gene can be induced by a subset of cytokines, including IL2, IL3 erythropoietin (EPO), GM-CSF, and interferon-gamma (IFN-γ).
::Evaluation of novel immune-based therapies using interferons, GM-CSF, G-CSF, thalidomide, IL-2, IL-12, cyclosporin (CsA), prednisone, cytotoxic agents, therapeutic immunization
The mutations cause expression of a defective α chain or complete absence thereof, an essential part of high-affinity interleukin-2 (IL-2) receptors.
IL-10 is capable of inhibiting synthesis of pro-inflammatory cytokines such as IFN-γ, IL-2, IL-3, TNFα and GM-CSF made by cells such as macrophages and regulatory T-cells.